Neural stem cell in-vitro induction method

By using insulin to optimize culture medium and induction protocol during the in vitro induction of neural stem cells, the problems of low survival rate and low differentiation efficiency of neural stem cells in the prior art were solved, which significantly improved the induction survival rate and differentiation ability of cells, and enhanced their Clinical application potential.

CN118909942APending Publication Date: 2024-11-08SHAANXI BEITIAN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411114093.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, the survival rate and differentiation efficiency of neural stem cells are low, which affect their effectiveness and clinical application potential in the in vitro induction process.

Method used

Using insulin as a medium component, combined with specific induction protocols, including pre-induction, directed induction and subculture steps, optimize the composition and conditions of the culture medium, such as the final concentration and time of insulin addition, to improve the induction survival rate and differentiation efficiency of neural stem cells. .

Benefits of technology

Through the addition of insulin, the number of aggregated cell clumps and secondary neurosphere formation of UC-MSCs was significantly improved, the self-renewal and differentiation ability of neural stem cells was improved, and the survival rate and differentiation efficiency during the induction process were significantly improved. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909942A_ABST
    Figure CN118909942A_ABST
Patent Text Reader

Abstract

The invention provides a neural stem cell in-vitro induction method, and belongs to the technical field of cell culture. The method provided by the invention comprises the steps of pre-induction culture, directional induction culture, subculture and the like, and a directional induction culture medium and a subculture medium containing insulin are adopted. The invention solves the problems of low survival rate and low differentiation efficiency of neural stem cells in the prior art. In the induction culture process of the neural stem cells, the insulin is used as a culture medium component, a specific induction scheme is combined, the UC-MSCs can be successfully and effectively induced to form the neural stem cell spheroid structure, after the insulin is added in the induction process of the neural stem cells, the number of cell agglomerates aggregated by the UC-MSCs is obviously increased, and the induction efficiency of the neural stem cells is improved. In addition, the secondary neurosphere obtained through the method is good in forming condition, and the UC-MSCs source neurosphere obtained through the method has excellent self-renewal capacity and differentiation capacity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of cell culture, and in particular to an in vitro induction method for neural stem cells. Background Art

[0002] Umbilical cord mesenchymal stem cells (UC-MSCs) are multipotent adult stem cells that exist in the Wharton's jelly tissue of the umbilical cord. They have the ability to self-renew and multidirectionally differentiate, and also have important immunomodulatory functions and paracrine effects. UC-MSCs are widely used to treat various neurological diseases. A large amount of data shows that UC-MSCs can differentiate into neurons and glial cells across germ layers.

[0003] Chinese patent CN101831401A discloses a method for inducing mesenchymal stem cells to differentiate into neural stem cells in vitro, wherein mesenchymal stem cells are pre-induced in a DMEM / DF-12 culture system supplemented with bFGF, fibroblast growth factor FGF8, SHH and leukemia inhibitory factor LIF; and the pre-induced cells are directed to differentiate into neural stem cells in a serum-free neurobasal medium culture system supplemented with bFGF, FGF8 and SHH. The invention has a high induction differentiation rate and is easy to differentiate into neurons, can reduce the formation of glial scars, and is more conducive to transplantation applications.

[0004] Chinese patent CN103031275A discloses an induction method for umbilical cord mesenchymal stem cells (UC-MSCs) to differentiate into neural stem cells, the induction method comprises the following steps: separation and primary culture of UC-MSCs, subculture and amplification of UC-MSCs, in vitro induction of UC-MSCs into neural stem cells, differentiation culture of neural stem cells and immunofluorescence detection. The induction method of the invention uses all-trans retinoic acid combined with basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) to induce umbilical cord mesenchymal stem cells to differentiate into neural stem cells, which still maintain strong vitality after multiple generations of division and proliferation. Trans-retinoic acid combined with cytokines induces UC-MSCs to transform into neural stem cells, realizing the ability of mesenchymal cells to differentiate into non-mesenchymal cells across germ layers, making it possible to become a more ideal seed cell for clinical application in the future.

[0005] However, the existing technology has the problems of low survival rate and low differentiation efficiency of neural stem cells. Summary of the invention

[0006] The purpose of the present invention is to provide a method for inducing neural stem cells in vitro, which can effectively improve the induced survival rate and differentiation efficiency of neural stem cells.

[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0008] The present invention provides a method for inducing neural stem cells in vitro, comprising the following steps:

[0009] S1. inoculating human umbilical cord mesenchymal stem cells into a pre-induction medium for pre-induction culture;

[0010] S2, transferring the cells obtained in S1 into a directional induction medium for directional induction culture;

[0011] S3, transferring the cells obtained in S2 into a subculture medium, and subculturing to obtain neural stem cells;

[0012] The directional induction medium and the subculture medium contain insulin.

[0013] Preferably, the final concentration of the insulin in the directed induction medium is 0.005-0.02 mg / mL.

[0014] Preferably, the final concentration of the insulin in the subculture medium is 0.005-0.02 mg / mL.

[0015] Preferably, the pre-induction culture time is 5 to 10 days.

[0016] Preferably, the pre-induction medium contains the following components at final concentrations:

[0017] 30~80ng / mL bFGF, 80~120ng / mL EGF, 400~600ng / mL SHH and 5~15ng / mL LIF.

[0018] Preferably, the time for the directed induction culture is 15 to 30 days.

[0019] Preferably, in step S2, the directed induction culture further comprises adding insulin to the directed induction culture medium;

[0020] The insulin supplementation scheme in the directed induction culture is 0.3-0.8 mg / time / d.

[0021] Preferably, in step S3, the subculture further comprises adding insulin to the subculture medium;

[0022] The insulin supplementation scheme in the subculture is 1.5 to 2.5 mg / time / d.

[0023] Preferably, the directional induction medium contains the following components at final concentrations: 1-3% N2 / B27 additive, 30-80 ng / mL bFGF, 80-120 ng / mL EGF and 400-600 ng / mL SHH.

[0024] Preferably, the subculture medium contains the following components at final concentrations: 1-3% N2 / B27 additive, 30-80 ng / mL bFGF and 80-120 ng / mL EGF.

[0025] Preferably, the culture conditions in S1 are:

[0026] Culture temperature: 35-39°C, CO2 concentration: 3-8%;

[0027] And / or, the culture conditions in S2 are:

[0028] Culture temperature: 35-39°C, CO2 concentration: 3-8%;

[0029] And / or, the culture conditions in S3 are:

[0030] Culture temperature: 35-39°C, CO2 concentration: 3-8%.

[0031] Beneficial effects of the present invention:

[0032] The present invention uses insulin as a culture medium component during the induction culture of neural stem cells, combined with a specific induction scheme, and can successfully induce UC-MSCs to effectively form a neural stem cell ball-like structure. After adding insulin during the neural stem cell induction process, the number of UC-MSCs aggregated into cell agglomerates increases significantly, and the secondary neurospheres obtained by the present invention are well formed. The UC-MSCs-derived neurospheres obtained by the present invention have excellent self-renewal and differentiation abilities. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 The diagrams show the spheroidization status of UC-MSCs at 2h, 4h, 6h, 12h, and 24h after induction of spheroidization;

[0034] Figure 2 After adding insulin to UC-MSCs to induce neurospheres (left), adding insulin to culture for 7 days after sphere formation (middle), and adding insulin to culture for 14 days after sphere formation (right);

[0035] Figure 3 UC-MSCs were induced into neurospheres without the addition of insulin (left), cultured for 7 days (middle), and cultured for 14 days (right);

[0036] Figure 4 The results of the self-renewal and multidirectional differentiation ability tests of neurospheres are shown in Figure 1, where A is the pre-induced neurosphere; B is the differentiation of neurospheres derived from UC-MSCs; C is the GFAP staining result of differentiated neurospheres;

[0037] Figure 5The expression of CD90 and CD105, common surface markers of UC-MSCs, before and after induction, where D0 is before expression induction, D1 is 1 day after expression induction into spheres, and D3 is 3 days after expression induction into spheres. DETAILED DESCRIPTION

[0038] The present invention provides a method for inducing neural stem cells in vitro, comprising the following steps:

[0039] S1. inoculating human umbilical cord mesenchymal stem cells into a pre-induction medium for pre-induction culture;

[0040] S2, transferring the cells obtained in S1 into a directional induction medium for directional induction culture;

[0041] S3, transferring the cells obtained in S2 into a subculture medium, and subculturing to obtain neural stem cells;

[0042] The directional induction medium and the subculture medium contain insulin.

[0043] In the present invention, the final concentration of insulin in the directed induction medium is preferably 0.005-0.02 mg / mL; the directed induction medium also preferably comprises the following components at final concentrations: 1-3% N2 / B27 additive, 30-80 ng / mL bFGF, 80-120 ng / mL EGF and 400-600 ng / mL SHH; the time of the directed induction culture is preferably 15-30 days; the directed induction culture also preferably includes the addition of insulin, and the insulin supplementation scheme in the directed induction culture is preferably 0.3-0.8 mg / time / d.

[0044] In the present invention, the pre-induction culture time is preferably 5 to 10 days; the pre-induction culture medium preferably contains the following components at final concentrations: 30 to 80 ng / mL bFGF, 80 to 120 ng / mL EGF, 400 to 600 ng / mL SHH and 5 to 15 ng / mL LIF.

[0045] In the present invention, the final concentration of insulin in the subculture medium is 0.005-0.02 mg / mL; the subculture medium also preferably contains the following components at final concentrations: 1-3% N2 / B27 additive, 30-80 ng / mL bFGF and 80-120 ng / mL EGF; the subculture also preferably includes supplementation of insulin; the insulin supplementation scheme in the subculture is preferably 1.5-2.5 mg / time / d.

[0046] In the present invention, the culture conditions in S1 to S3 are preferably: culture temperature: 35 to 39°C, CO2 concentration of 3 to 8%; the culture in the present invention preferably includes the steps of cell washing, digestion and re-inoculation, wherein the washing preferably uses a NaCl aqueous solution as a detergent, and the concentration of the NaCl aqueous solution is 0.8 to 1.0%; the digestion reagent used in the digestion is preferably a trypsin-EDTA digestion solution; the inoculum size of the re-inoculation is preferably 1.2×10 6 Pieces / bottle.

[0047] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0048] Example

[0049] Pre-induction

[0050] 1) P4 human umbilical cord mesenchymal stem cells were obtained. When the cells adhered to the wall and grew to 85% confluence, the original culture medium in the culture bottle was removed, 10 mL of 0.9% NaCl was gently added to the culture bottle for washing, and the washing solution was discarded;

[0051] 2) Add 2.0 mL of 0.25% trypsin-0.01% EDTA digestion solution to cover the bottom of the bottle. When cells are observed to float in a round shape under an inverted microscope, add 5.0 mL of FBS to stop trypsin digestion;

[0052] 3) After repeated washing, collect the liquid, add 10 mL of 0.9% NaCl to wash once, centrifuge at 1200 rpm for 6 minutes at room temperature: discard the supernatant, add 10 mL of DMEM / F12 medium to resuspend the cells, and inoculate 1.2×10 6 cells;

[0053] 4) Culture: DMEM / F12 medium (containing 10% fetal bovine serum) supplemented with 50 ng / mL bFGF, 100 ng / mL EGF, 500 ng / mL SHH and 10 ng / mL LIF, with a total volume of 25 mL / bottle. Culture in a 37°C, 5% CO2 incubator for 7 days, with the medium changed every 3 days.

[0054] Directed induction of umbilical cord mesenchymal stem cells into neural stem cells

[0055] Add 2.0 mL of 0.25% trypsin-0.01% EDTA digestion solution to the pre-induced cells, and cover the bottom of the bottle. When the cells are observed to float in a round shape under an inverted microscope, add 5.0 mL of FBS to stop the trypsin digestion.

[0056] After repeated washing by blowing, the liquid was collected, and then 10 mL of 0.9% NaCl was added for washing once, and centrifuged at 1200 rpm for 6 minutes at room temperature; after discarding the supernatant, 10 mL of neuronal cell culture medium (Stempro TM Resuspend the cells in NSC SFM and re-seed in T175m 2 In culture flask;

[0057] Preparation of insulin solution: Dissolve insulin dry powder in hydrochloric acid solution at pH 2.0 to obtain an insulin solution with a concentration of 2 mg / ml. Filter and dispense into EP tubes, 0.25 ml each, and store at -20°C.

[0058] Culture system: Serum-free medium containing 2% N2 / B27, supplemented with 50ng / mL bFGF, 100ng / mL EGF and 500ng / mL SHH, and directional induction medium with a final concentration (concentration of insulin dry powder in the whole culture medium) of 0.01mg / mL insulin, with a total volume of 25mL / bottle. Culture in a 37°C, 5% CO2, saturated humidity incubator for 20 days, add 0.5ml insulin solution every 2 days, add growth factors every 3 days (each supplement amount: 20ng / mL bFGF, 20ng / mL EGF, 20ng / mL SHH), and change the medium every 7 days.

[0059] Subculture

[0060] The culture medium and induced UC-NSCs were pipetted into a centrifuge tube, centrifuged at 1200 rpm for 6 minutes, and the supernatant was discarded;

[0061] Add subculture medium (Stempro supplemented with 2% N2 / B27, 50 ng / mL bFGF and 100 ng / mL EGF and a final concentration of 0.01 mg / mL insulin) TM NSC SFM serum-free neural stem cell culture medium) to disperse large cell clusters into single cells or small cell clusters, and pass them at a ratio of 1:3:

[0062] The cells after subculture were transferred into new subculture medium and cultured at 37°C and 5% CO2, with 1 ml of insulin solution added every 3 days.

[0063] Comparative Example 1

[0064] The only difference from the embodiment is that no insulin is added to any culture medium during the entire culture process, and other culture conditions are exactly the same.

[0065] Comparative Example 2

[0066] The only difference from the embodiment is that the culture medium used in the whole culture process is DMEM / F12 culture medium (20 ng / mL bFGF, 20 ng / mL EGF) containing 2% B27, and the total volume of the culture medium is 25 mL / bottle. The culture is placed in a 37°C, 5% CO2 incubator, and the medium is changed every 3 days.

[0067] Experimental example

[0068] The following identifications were performed on the neural cell clusters induced and formed in the embodiments and comparative examples:

[0069] Morphological observation: observe and record the changes in morphological characteristics of neural differentiation of umbilical cord mesenchymal stem cells induced in vitro. The results are shown in Figure 1 .

[0070] The cell changes induced by adding insulin and the cell changes induced by not adding insulin were observed under the microscope. The results are shown in Figures 2-3 .

[0071] The results show that the UC-MSCs in the present invention are effectively induced to form neural stem cell sphere-like structures. After adding insulin during the neural stem cell induction process, the number of cell clusters formed by UC-MSCs increases significantly.

[0072] Comparison of survival rate of induced neural stem cells:

[0073] Using the solution provided by the present invention, UC-MSCs will quickly aggregate into cell clusters, forming irregular spherical structures, and at the same time, many relatively loose cell cluster-like structures will be formed. These cell clusters are actually newborn neurospheres, which will gradually form typical neurosphere structures later. The survival rates of neural stem cells at different stages of induction are statistically analyzed, and the results are shown in Table 1.

[0074] Table 1 Neural stem cell survival results

[0075]

[0076]

[0077] The self-renewal and differentiation abilities of the UC-MSCs-derived neurospheres prepared in the example were tested:

[0078] Self-renewal capacity detection: UC-MSCs-derived neurospheres were collected and broken into single cells, and then resuspended in neural stem cell culture medium and placed in 24- or 96-well plates to observe the formation of secondary neurospheres. From the third day, some wells began to form neurospheres, and by the fifth day, almost all wells had neurospheres formed. Figure 4 As shown in A.

[0079] Multidirectional differentiation ability test: Select some neurospheres and place them on the coverslip of a six-well plate, then use DMEN / F12 medium containing 2% fetal bovine serum to induce neurosphere differentiation. Figure 4 B; After 6 days, the differentiation was detected by immunofluorescence staining. Figure 4 As shown in C.

[0080] Immunophenotyping

[0081] 1. Take the third generation UC-MSCs with good growth, digest them with 0.25% trypsin, and resuspend them in PBS buffer to make 1×10 6 / mL cell suspension;

[0082] 2. Take 1 mL of cell suspension and add rabbit anti-human CD90, CD105, CD34 primary antibodies, mix gently, and incubate at 4°C in the dark for 30 minutes;

[0083] 3. Wash twice with PBS buffer, add FITC and PE labeled goat anti-rabbit IgG secondary antibody, react at 4℃ for 30min;

[0084] 4. Wash twice with PBS buffer, fix with 4% paraformaldehyde, resuspend in PBS and detect with flow cytometer;

[0085] 5. The UC-MSCs-derived neurospheres (1 day and 3 days after induction) in the example were digested with trypsin into single cell suspensions and then subjected to flow cytometry detection according to the above method. The expression rates of surface markers CD90 and CD105 before and 1d and 3d after induction of UC-MSCs, as well as the expression of CD13, CD44, CD90, CD105, CD14, and CD34 before and after induction into spheres were detected. The results are shown in FIG. Figure 5 and as shown in Table 2 below.

[0086] Table 2 Expression rates of common surface markers of UC-MSCs before and after induction into spheres

[0087]

[0088]

[0089] The results showed that the expression of CD13, CD90 and CD105 decreased on the third day of sphere formation (p < 0.01), and the expression of CD44 began to decrease from the first day of sphere formation (p < 0.01), and decreased significantly on the third day (p < 0.01).

[0090] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for inducing neural stem cells in vitro, characterized in that: The following steps are involved: S1. inoculating human umbilical cord mesenchymal stem cells into a pre-induction medium for pre-induction culture; S2, transferring the cells obtained in S1 into a directional induction medium for directional induction culture; S3, transferring the cells obtained in S2 into a subculture medium, and subculturing to obtain neural stem cells; The directional induction medium and the subculture medium contain insulin.

2. The in vitro induction method of neural stem cells according to claim 1, characterized in that: The final concentration of the insulin in the directional induction medium is 0.005-0.02 mg / mL.

3. The in vitro induction method of neural stem cells according to claim 1, characterized in that: The final concentration of the insulin in the subculture medium is 0.005-0.02 mg / mL.

4. The in vitro induction method of neural stem cells according to claim 1, characterized in that: The time of the pre-induction culture is 5 to 10 days.

5. The in vitro induction method of neural stem cells according to claim 1, characterized in that: The pre-induction medium contains the following components at final concentrations: 30~80ng / mL bFGF, 80~120ng / mL EGF, 400~600ng / mL SHH and 5~15ng / mL LIF.

6. The in vitro induction method of neural stem cells according to claim 1, characterized in that: The time of the directed induction culture is 15 to 30 days; Preferably, in step S2, the directed induction culture further comprises adding insulin to the directed induction culture medium; The insulin supplementation scheme in the directed induction culture is 0.3-0.8 mg / time / d.

7. The in vitro induction method of neural stem cells according to claim 1, characterized in that: In step S3, the subculture further comprises adding insulin to the subculture medium; The insulin supplementation scheme in the subculture is 1.5 to 2.5 mg / time / d.

8. The in vitro induction method of neural stem cells according to claim 1, characterized in that: The directional induction medium contains the following components at final concentrations: 1-3% N2 / B27 additive, 30-80 ng / mL bFGF, 80-120 ng / mL EGF and 400-600 ng / mL SHH.

9. The in vitro induction method of neural stem cells according to claim 1, characterized in that: The subculture medium contains the following components at final concentrations: 1-3% N2 / B27 additive, 30-80 ng / mL bFGF, and 80-120 ng / mL EGF.

10. The method for inducing neural stem cells in vitro according to any one of claims 1 to 9, characterized in that: The culture conditions described in S1 are: Culture temperature: 35-39°C, CO2 concentration: 3-8%; And / or, the culture conditions in S2 are: Culture temperature: 35-39°C, CO2 concentration: 3-8%; And / or, the culture conditions in S3 are: Culture temperature: 35-39°C, CO2 concentration: 3-8%.